Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by improving the visibility of tumors.
Vergent’s lead investigational compound, abenacianine for injection (VGT-309), is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating abenacianine for injection in lung cancer, with the potential to expand its application to a wide range of solid tumors.
Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.
* Abenacianine for injection is an investigational product and has not been approved by the U.S. Food and Drug Administration (FDA) for any indication.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 5810 West 78th Street,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://bit.ly/3M0vcvy
- HQ
- Minneapolis, MN
Vergent Bioscience Questions
Vergent Bioscience's website is https://bit.ly/3M0vcvy
Vergent Bioscience's LinkedIn profile is https://www.linkedin.com/company/vergent-bioscience
Vergent Bioscience has
11 employees.
View email and phone details for 11
employees at Vergent Bioscience.
Vergent Bioscience's industry is
Biotechnology Research
Vergent Bioscience's top competitors are
Oncolux Inc,
Horizon Surgical Systems,
Mendaera, Inc.,
Revolve Surgical,
Spiro Robotics,
Panda Surgical,
Scialytics,
Vitestro,
Hypervision Surgical,
Virtuoso Surgical, Inc..
Vergent Bioscience's categories are Biotechnology Research
Vergent Bioscience's founding year is 2016
